Patents by Inventor Damian Brockschnieder

Damian Brockschnieder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210220358
    Abstract: The present invention relates to use 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds for the treatment or prophylaxis of diseases which are associated with nerve fibre sensitization, in particular for treatment and prophylaxis of Chronic Cough (CC), Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disorder (COPD), and asthma.
    Type: Application
    Filed: May 14, 2019
    Publication date: July 22, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Christian FRIEDRICH, Isabella GASHAW, Damian BROCKSCHNIEDER, Oliver Martin FISCHER
  • Publication number: 20210147504
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 20, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Damian BROCKSCHNIEDER, Jan TEBBE, Andreas WILMEN, Frank WUNDER
  • Publication number: 20210139555
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 13, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, Ilka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
  • Publication number: 20210079056
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 18, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Damian BROCKSCHNIEDER, Lucas Hudson HOFMEISTER, Claudia NOACK, Jan TEBBE, Stuart WALSH, Andreas WILMEN, Frank WUNDER
  • Publication number: 20200375986
    Abstract: The invention relates to prolyl endopeptidase (PREP) inhibitors which contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system, methods for producing same, the use thereof alone or in combinations for treating and/or preventing diseases, and the use thereof for producing drugs for treating and/or preventing diseases, in particular for treating and/or preventing inflammatory lung diseases (COPD).
    Type: Application
    Filed: October 31, 2018
    Publication date: December 3, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Nicole BIBER, Damian BROCKSCHNIEDER, Florian KÖLLING, Jörg MEDING, Hideki MIYATAKE ONDOZABAL, Thomas NEUBAUER, Martina SCHÄFER, Dmitry ZUBOV, Carsten TERJUNG
  • Patent number: 10722501
    Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: July 28, 2020
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Nicole Biber, Damian Brockschnieder, Kersten Matthias Gericke, Florian Kölling, Klemens Lustig, Jörg Meding, Heinrich Meier, Thomas Neubauer, Martina Schäfer, Andreas Timmermann, Dmitry Zubov, Carsten Terjung, Niels Lindner, Volker Badock, Dieter Moosmayer, Hideki Miyatake Ondozabal, Stephen Moore, Alexander Schulz
  • Publication number: 20190160048
    Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.
    Type: Application
    Filed: May 8, 2017
    Publication date: May 30, 2019
    Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Nicole BIBER, Damian BROCKSCHNIEDER, Kersten Matthias GERICKE, Florian KÖLLING, Klemens LUSTIG, Jörg MEDING, Heinrich MEIER, Thomas NEUBAUER, Martina SCHÄFER, Andreas TIMMERMANN, Dmitry ZUBOV, Carsten TERJUNG, Niels LINDNER, Volker BADOCK, Dieter MOOSMAYER, Hideki MIYATAKE ONDOZABAL, Steven MOORE, Alexander SCHULZ
  • Patent number: 10292970
    Abstract: The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: May 21, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Volkhart Min-Jian Li
  • Patent number: 10214526
    Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: February 26, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Min Jian Volkhart Li
  • Patent number: 10174021
    Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridines of the formula (I-A) to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: January 8, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Volkhart Min-Jian Li
  • Patent number: 10150773
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides of general formula (I) to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: December 11, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Min Jian Volkhart Li
  • Publication number: 20180037580
    Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: February 2, 2016
    Publication date: February 8, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Min Jian Volkhart LI
  • Publication number: 20180022751
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: February 2, 2016
    Publication date: January 25, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Min Jian Volkhart LI
  • Publication number: 20170313700
    Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: November 30, 2015
    Publication date: November 2, 2017
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Volkhart Min-Jian LI
  • Publication number: 20170304278
    Abstract: The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: November 30, 2015
    Publication date: October 26, 2017
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Volkhart Min-Jian LI
  • Publication number: 20170240566
    Abstract: The present application relates to novel amino-substituted fused pyrimidines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 24, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros VAKALOPOULOS, Gaelle VALOT, Markus FOLLMANN, Damian BROCKSCHNIEDER, Johannes-Peter STASCH, Tobias MARQUARDT, Adrian TERSTEEGEN, Frank WUNDER, Lisa DIETZ, Dieter LANG, Ursula KRENZ
  • Publication number: 20170233413
    Abstract: The present application relates to novel substituted fused pyrimidines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 17, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Walter HÜBSCH, Alexandros VAKALOPOULOS, Markus FOLLMANN, Gaelle VALOT, Johannes-Peter STASCH, Damian BROCKSCHNIEDER, Tobias MARQUARDT, Frank WUNDER, Adrian TERSTEEGEN, Lisa DIETZ, Dieter LANG, Niels LINDNER
  • Patent number: 9688699
    Abstract: The present application relates to novel 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: June 27, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Alexey Gromov, Markus Follmann, Damian Brockschnieder, Johannes-Peter Stasch, Tobias Marquardt, Adrian Tersteegen, Frank Wunder, Gorden Redlich, Dieter Lang, Volkhart Min-Jian Li
  • Patent number: 9605008
    Abstract: The present application relates to novel benzyl-1H-pyrazolo[3,4-b]pyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: March 28, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Alexey Gromov, Markus Follmann, Damian Brockschnieder, Johannes-Peter Stasch, Tobias Marquardt, Adrian Tersteegen, Frank Wunder, Gorden Redlich, Dieter Lang, Volkhart Min-Jian Li
  • Publication number: 20170057958
    Abstract: The present application relates to novel 6-hydrogen-substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: April 29, 2015
    Publication date: March 2, 2017
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Markus Follmann, Johannes-Peter Stasch, Damian Brockschnieder, Frank Wunder, Tobias Marquardt, Lisa Dietz, Thomas Mondritzki, Dieter Lang, Volkhart Min-Jian Li